Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 101.0 Zaltrap (ziv-aflibercept)
Zaltrap (ziv-aflibercept) acts as a soluble receptor that binds to human VEGF-A, to human VEGF-B), and to human PlGF. By binding to these endogenous ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This inhibition can result in decreased neovascularization and decreased vascular permeability.
MBP 187.0 Zemdri (plazomicin)
Zemdri (plazomicin) is an aminoglycoside, which acts by binding to bacterial 30S ribosomal subunit, inhibiting protein synthesis.
MBP 222.0 Zepzelca (lurbinectedin)
Zepzelca (lurbinectedin) is an alkylating agent and a selective inhibitor of oncogenic transcription which binds preferentially to guanine residues in the minor groove of DNA; this forms adducts and bends the DNA helix towards the major groove. Adduct formation affects the activities of DNA binding proteins, including some transcription factors and DNA repair pathways. Inhibition of oncogenic transcription results in tumor cell apoptosis.
New Policy 9/15/20
MBP 205.0 Zerbaxa (ceftolozane/tazobactam)
Zerbaxa (ceftolozane/tazobactam) is a cephalosporin combination. Ceftolozane inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Ceftolozane is an inhibitor of PBPs of Pseudomonas aeruginosa (e.g., PBP1b, PBP1c and PBP3) and Escherichia coli (e.g., PBP3). Tazobactam irreversibly inhibits some beta-lactamases (eg, certain penicillinases and cephalosporinases), and can covalently bind to some plasmid-mediated and chromosomal bacterial beta-lactamases.
MBP 15.0 Zevalin (Ibritumomab tiuxetan (IDEC Y2B8))
Zevalin® (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan. Zevalin binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35) and prevents shedding from the cell surface and internalization upon antibody binding.
MBP 178.0 Zilretta (triamcinolone acetonide ER injection)
Zilretta (triamcinolone acetonide ER injection) is an extended-release intra-articular injection of triamcinolone that is indicated for the management of osteoarthritis pain of the knee. It is a long acting corticosteroid with minimal sodium-retaining potential. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.
MBP 153.0 Zinplava (bezlotoxumab)
Zinplava (bezlotoxumab) is a human IgG1 monoclonal antibody that binds to C. difficile toxin B and neutralizes it to prevent its toxic effects; bezlotoxumab does not bind to C. difficile toxin A.
MBP 199.0 Zolgensma (onasemnogene abeparvovec-xioi)
Zolgensma (onasemnogene abeparvovec-xioi) is a recombinant adeno-associated virus vector-based gene therapy that delivers a normal copy of the gene encoding human survival motor neuron (SMN) protein.
MBP 201.0 Zulresso (brexanolone)
Zulresso (brexanolone) is a gamma-aminobutyric acid (GABA)-A receptor positive modulator indicated for the treatment of postpartum depression in adults. The exact mechanism of action is not fully understood, but is thought to be related to positive allosteric modulation of GABA-A receptors.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.